CN101489986A - 曲美布汀和n-去甲基曲美布汀的盐 - Google Patents

曲美布汀和n-去甲基曲美布汀的盐 Download PDF

Info

Publication number
CN101489986A
CN101489986A CNA2007800264544A CN200780026454A CN101489986A CN 101489986 A CN101489986 A CN 101489986A CN A2007800264544 A CNA2007800264544 A CN A2007800264544A CN 200780026454 A CN200780026454 A CN 200780026454A CN 101489986 A CN101489986 A CN 101489986A
Authority
CN
China
Prior art keywords
trimebutine
compound
nitroarginine
salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800264544A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·沃雷斯
G·西里诺
V·桑塔加达
G·卡里安多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antibe Therapeutics Inc
Original Assignee
Antibe Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antibe Therapeutics Inc filed Critical Antibe Therapeutics Inc
Publication of CN101489986A publication Critical patent/CN101489986A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/30—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
    • C07C279/32—N-nitroguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800264544A 2006-06-06 2007-06-06 曲美布汀和n-去甲基曲美布汀的盐 Pending CN101489986A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80406706P 2006-06-06 2006-06-06
US60/804,067 2006-06-06

Publications (1)

Publication Number Publication Date
CN101489986A true CN101489986A (zh) 2009-07-22

Family

ID=38801016

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800264544A Pending CN101489986A (zh) 2006-06-06 2007-06-06 曲美布汀和n-去甲基曲美布汀的盐

Country Status (10)

Country Link
US (2) US7666907B2 (https=)
EP (1) EP2024323B1 (https=)
JP (1) JP5421098B2 (https=)
KR (1) KR20090021346A (https=)
CN (1) CN101489986A (https=)
AU (1) AU2007257174B2 (https=)
BR (1) BRPI0712417A2 (https=)
CA (1) CA2653869A1 (https=)
RU (1) RU2008152751A (https=)
WO (1) WO2007140611A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114190383A (zh) * 2021-12-06 2022-03-18 南京天秾生物技术有限公司 2-氨基-3-苯基丁酸或2,6-二氨基-3-甲基己酸作为植物免疫诱抗剂的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US7932286B2 (en) * 2007-07-31 2011-04-26 Martin Francois Method for treating colonic viscerosensitivity and spasticity
FR2927076B1 (fr) * 2008-01-31 2010-03-26 Oroxcell Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2827887C (en) * 2011-08-15 2020-06-09 Research Foundation Of The City University Of New York No- and h2s-releasing compounds
RU2014138619A (ru) * 2012-03-12 2016-05-10 Джикеа Фарма Инк. Новые соли тримебутина на основе сульфонатов
JP2017528505A (ja) 2014-09-25 2017-09-28 ザ・ホスピタル・フォー・シック・チルドレンＴｈｅ Ｈｏｓｐｉｔａｌ Ｆｏｒ Ｓｉｃｋ Ｃｈｉｌｄｒｅｎ 発毛増進、皮膚再生促進及び創傷治癒のための組成物及び方法
RU2752086C1 (ru) * 2020-04-27 2021-07-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новое соединение [2-(диметиламино)-2-фенилбутил]-3,4,5-триметоксибензоата 4-метил-2н-хромен-2-он-7-илсульфат и его применение

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460919A1 (fr) * 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
JPS57500432A (https=) * 1980-03-20 1982-03-11
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5245080A (en) * 1989-02-20 1993-09-14 Jouveinal Sa (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-N-propylamine, process for preparing it and its therapeutical use
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
WO1997009329A1 (en) 1995-09-08 1997-03-13 J. Uriach & Cia. S.A. Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
AU7246398A (en) * 1997-04-30 1998-11-24 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
EP1110549A1 (en) * 1999-12-23 2001-06-27 Warner-Lambert Company Use of trimebutine for treating pain
SV2001000242A (es) * 1999-12-23 2001-10-25 Warner Lambert Co Combinacion de trimebutina con un analgesico derivado del opio
JP2003532703A (ja) * 2000-05-05 2003-11-05 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） 新規アミノ酸誘導体及びその医薬としての使用
AU2001279064A1 (en) * 2000-07-27 2002-02-13 Rutgers, The State University Therapeutic azo-compounds for drug delivery
ATE460394T1 (de) * 2000-08-29 2010-03-15 Biocon Ltd 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
BR0312501A (pt) * 2002-07-10 2005-04-12 Warner Lambert Co Combinação de um inibidor alostérico ou metaloproteinase de matriz-13 com um inibidor de ciclooxigenase-2 diferente de celecoxib ou valdecoxib
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
EP1886681A3 (en) 2004-10-07 2008-11-19 Sulfidris S.r.l. 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione valproate ester

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114190383A (zh) * 2021-12-06 2022-03-18 南京天秾生物技术有限公司 2-氨基-3-苯基丁酸或2,6-二氨基-3-甲基己酸作为植物免疫诱抗剂的应用

Also Published As

Publication number Publication date
EP2024323A4 (en) 2010-07-28
US20070275905A1 (en) 2007-11-29
WO2007140611A1 (en) 2007-12-13
KR20090021346A (ko) 2009-03-03
JP5421098B2 (ja) 2014-02-19
CA2653869A1 (en) 2007-12-13
RU2008152751A (ru) 2010-07-20
US20110144188A1 (en) 2011-06-16
EP2024323A1 (en) 2009-02-18
AU2007257174A1 (en) 2007-12-13
AU2007257174B2 (en) 2012-07-12
JP2009539777A (ja) 2009-11-19
BRPI0712417A2 (pt) 2012-09-04
EP2024323B1 (en) 2013-03-27
US7666907B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
CN101489986A (zh) 曲美布汀和n-去甲基曲美布汀的盐
JP5221341B2 (ja) ４−または５−アミノサリチル酸誘導体
CA2660814C (en) Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
IE49701B1 (en) Amides of acyl-carnitines,process for preparing same and pharmaceutical compositions containing such amides
HU220625B1 (hu) Metalloproteáz enzimeket gátló hidroxámsavszármazékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás e vegyületek előállítására
AU2006346195A1 (en) Positively charged water-soluble prodrugs of aspirin
CN101337984A (zh) 熊果烷型五环三萜氨基酸衍生物、其制备方法及其医药用途
CN115181154B (zh) Pyxinol酰胺衍生物及其制备方法以及在药物领域中的应用
CN104603096A (zh) 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
CN101475484B (zh) 骨靶向抗炎药物合成方法及其应用
CN101490029B (zh) 药物的4-羟基硫代苯甲酰胺衍生物
CN102190622B (zh) 依达拉奉的水溶性衍生物及其制备方法和应用
CN114890979A (zh) 一种多巴寡肽的中间体的合成方法及其用途、组合物和制剂
RU2751770C2 (ru) Композиции и способы лечения синдрома раздраженного кишечника
CN100513415C (zh) 胆汁酸衍生物及其医药用途
CN104364230A (zh) 用于治疗糖尿病的组合物和方法
RU2853885C1 (ru) Новая кристаллическая форма [2-(диметиламино)-2-фенилбутил]-3,4,5-триметоксибензоата 4-метил-2н-хромен-2-он-7-илсульфата
CN104961646B (zh) 莫沙必利的活性代谢物及其制备方法和用途
CN1266429A (zh) 新的季戊四醇衍生物、其制备与应用以及合成该衍生物的中间体产物
HU198446B (en) Process for production of new amids of buten acid and medical compositions containing such active substances
WO2015022613A1 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
CN104892449A (zh) 一种精胺类似物及其药用盐的制备方法和用途
WO2014147541A2 (en) Compositions and methods for the treatment of peptic ulcers and gastrointestinal diseases
WO2013168015A1 (en) Compositions and methods for the treatment of asthma and allergy
WO2013168007A1 (en) Compositions and methods for the treatment of cardiovascular and neurological diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090722